Working… Menu
Trial record 1 of 1 for:    NCT02914366
Previous Study | Return to List | Next Study

Ambroxol as a Treatment for Parkinson's Disease Dementia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02914366
Recruitment Status : Recruiting
First Posted : September 26, 2016
Last Update Posted : June 22, 2020
Weston Brain Institute
University of Western Ontario, Canada
London Health Sciences Centre
Information provided by (Responsible Party):
Stephen Pasternak, University of Western Ontario, Canada

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : December 2021
Narita A, Kubota N, Takayama R, Takahashi Y, Maegaki Y, Suzuki Y, & Ohno K. Chaperone therapy for neuronopathic Gaucher disease. Molecular Genetics and Metabolism, 108(2): S69, 2013.
Narita A, Zhuo L, Higaki K, Togawa M, Maegaki Y, Nanba E, Suzuko Y, Ohno K: Chemical chaperone therapy for neuropathic Gaucher disease. In 12th International Child Neurology Congress and the 11th Asian and Oceanian Congress of Child Neurology Brisbane. QLD Australia: Developmental Medicine and Child Neurology (54): 50-51, 2012.

Publications automatically indexed to this study by Identifier (NCT Number):